Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 201–300 of 860
Bidinosti, M., Ran, I., Sanchez-Carbente, M. R., Martineau, Y., Gingras, A.-C., Gkogkas, C., Raught, B., Bramham, C. R., Sossin, W. S., Costa-Mattioli, M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.022 · Cited by 100
“In neuronal systems, mTOR modulates several processes, including learning and memory (Ehninger et al., 2008; Parsons et al., 2006), synaptic plasticity (Cammalleri et al., 2003; Tang et al., 2002), dendritic protein synthesis (Gobert et al., 2008; Takei et al., 2004; Tsokas et al., 2005), and…”
Cellular and synaptic network defects in autism
Peça, J., & Feng, G. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.02.015 · Cited by 96
Translational control by eIF2α kinases in long-lasting synaptic plasticity and long-term memory
Trinh, M. A., & Klann, E. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.04.013 · Cited by 113
Therapeutic targeting of mTOR in tuberous sclerosis
Sampson, J. R. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370259 · Cited by 100
Neural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders
Gandhi, T., & Lee, C. C. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592710 · Cited by 88
Feliciano, D. M., Lin, T. V., Hartman, N. W., Bartley, C. M., Kubera, C., Hsieh, L. S., Lafourcade, C., O’Keefe, R. A., & Bordey, A. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.02.008 · Cited by 95
Winden, K. D., Sundberg, M., Yang, C., Wafa, S. M. A., Dwyer, S., Chen, P.-F., Buttermore, E. D., & Sahin, M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0642-19.2019 · Cited by 93
“…in patients with TSC. Patients with TSC frequently have heterozygous loss of function variants in either TSC1 or TSC2, but most animal models with heterozygous mutations demonstrate subtle or no symptoms (Uhlmann et al., 2002; Goorden et al., 2007; Ehninger et al., 2008; Yuan et al., 2012).”
BackgroundStoppel, L. J., Kazdoba, T. M., Schaffler, M. D., Preza, A. R., Heynen, A., Crawley, J. N., & Bear, M. F. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.236 · Cited by 92
“Context discrimination was performed in a Freezeframe Chamber (Coulbourn Instrument) as previously described (Auerbach et al, 2011; Ehninger et al, 2008).”
MethodPlasticity of dendritic spines: Molecular function and dysfunction in neurodevelopmental disorders
Nishiyama, J. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12899 · Cited by 91
“Consistent with this idea, mice engineered to carry heterozygous lossof-function mutations in TSC1 or TSC2 have hippocampus-dependent learning and memory deficits.(102,103) However, in contrast to Fmr1 knockout mice, heterozygous TSC2 mice show a decreased translation of ARC mRNA and mGluR-LTD in the hippocampus.”
BackgroundPI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
Hillmann, P., & Fabbro, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225792 · Cited by 97
“While inhibition of mTOR signaling by rapalogs has positive effects on behavior, reduces tumor formation, and suppresses seizures in animal models [82,83], their chronic use is hampered by their immunosuppressive nature.”
BackgroundAutism Spectrum Disorders: Translating human deficits into mouse behavior
Pasciuto, E., Borrie, S. C., Kanellopoulos, A. K., Santos, A. R., Cappuyns, E., D’Andrea, L., Pacini, L., & Bagni, C. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.07.013 · Cited by 91
Kaphzan, H., Hernandez, P. J., Jung, J. I., Cowansage, K. K., Deinhardt, K., Chao, M. V., Abel, T. G., & Klann, E. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.021 · Cited by 103
Dissociation of the Pharmacological Effects of THC by mTOR Blockade
Puighermanal, E., Busquets-García, A., Gomis‐González, M., Marsicano, G., Maldonado, R. J., & Ozaita, A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.31 · Cited by 109
“Moreover, enhanced levels of mTOR activity have been described in animal models presenting cognitive deficits such as the Tsc2þ / mice or Fmr1 knockout mice (Ehninger et al, 2008; Sharma et al, 2010).”
BackgroundThe mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis
Russo, E., Citraro, R., Constanti, A., & Sarro, G. D. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8314-5 · Cited by 98
Way, S. W., Rozas, N. S., Wu, H. C., McKenna, J., Reith, R. M., Hashmi, S. S., Dash, P. K., & Gambello, M. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds156 · Cited by 92
“03) (C) Left panel: latency to platform during a 1-day MWM training protocol (n 1⁄4 8 both groups; two-way repeated-measures of ANOVA with treatment and trial number as between-subjects factors: F(1,14) 1⁄4 3.”
BackgroundMethodBasal ganglia and autism – a translational perspective
Subramanian, K., Brandenburg, C., Orsati, F., Soghomonian, J., Hussman, J. P., & Blatt, G. J. (2017) · Autism Research · doi:10.1002/aur.1837 · Cited by 88
“…and autism INSAR Various social behavior and learning difficulties have been described as well as increases in compulsive behavior [Auerbach, Osterweil, & Bear, 2011; Ehninger et al., 2009; Goorden, Van Woerden, Van Der Weerd, Cheadle, & Elgersma, 2007; Reith et al., 2013; Tsai et al., 2012].”
BackgroundSirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial
Overwater, I. E., Rietman, A. B., Bindels-de Heus, K., Looman, C. W. N., Rizopoulos, D., Sibindi, T. M., Cherian, P. J., Jansen, F. E., Moll, H. A., Elgersma, Y., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003077 · Cited by 89
Creson, T. K., Rojas, C., Hwaun, E., Vaissière, T., Kılınç, M., Jiménez-Gómez, A., Holder, J. L., Tang, J., Colgin, L. L., Miller, C. A., et al. (2019) · eLife · doi:10.7554/elife.46752 · Cited by 94
“In these models, with some notable exceptions, phenotypic reversal in adulthood is most effective in correcting social behaviors and/or motor function (Guy et al., 2007; Ehninger et al., 2008b; Marı́n, 2016; Mei et al., 2016).”
BackgroundInfluentialPenney, J., Tsurudome, K., Liao, E. H., Elazzouzi, F., Livingstone, M., Gonzalez, M., Sonenberg, N., & Haghighi, A. P. (2012) · Neuron · doi:10.1016/j.neuron.2012.01.030 · Cited by 90
“…as tuberous sclerosis complex (TSC), autism, mental retardation, and schizophrenia, where regulation of TOR activity may be altered (Buckmaster et al., 2009; Ehninger et al., 2008; Emamian et al., 2004; Hoeffer and Klann, 2010; Kelleher and Bear, 2008; Sharma et al., 2010; Swiech et al., 2008).”
BackgroundCholesterol homeostasis: a key to prevent or slow down neurodegeneration
Anchisi, L., Dessì, S., Pani, A., & Mandas, A. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2012.00486 · Cited by 91
Metformin for treatment of fragile X syndrome and other neurological disorders
Gantois, I., Popic, J., Khoutorsky, A., & Sonenberg, N. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-041238 · Cited by 87
Giovannini, M. G., Lana, D., & Pepeu, G. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2014.12.014 · Cited by 97
“are associated with memory deficits (Ehninger et al., 2008).”
mTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86
“These effects were reversed by administering the mTOR inhibitor rapamycin [72].”
BackgroundRapamycin Is Neuroprotective in a Rat Chronic Hypertensive Glaucoma Model
Su, W., Li, Z., Jia, Y., & Zhuo, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099719 · Cited by 96
“Recently, rapamycin-mediated neuroprotective effects in the CNS and peripheral nervous system have received increasing attention [5,8].”
BackgroundCopf, T. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.008 · Cited by 98
“In regard to potential therapies, a brief treatment with one of the mTOR inhibitors, rapamycin, delivered to adult TS mice, can rescue both the TS-associated synaptic plasticity and the behavioral deficits [484],”
Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice
Steinmetz, A. B., Stern, S. A., Kohtz, A. S., Descalzi, G., & Alberini, C. M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2010-17.2017 · Cited by 96
Tsai, P., & Sahin, M. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834451c4 · Cited by 84
Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy
Lipton, J. O., Boyle, L. M., Yuan, E. D., Hochstrasser, K. J., Chifamba, F. F., Nathan, A., Tsai, P. T., Davis, F., & Sahin, M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.008 · Cited by 86
“Tsc2 mice have been shown to demonstrate abnormalities in axon guidance, synaptic plasticity, and cognitive function (Ehninger et al., 2008; Nie et al., 2010).”
BackgroundCuratolo, P., Napolioni, V., & Moavero, R. (2010) · Journal of Child Neurology · doi:10.1177/0883073810361789 · Cited by 87
Chévere-Torres, I., Kaphzan, H., Bhattacharya, A., Kang, A., Maki, J. M., Gambello, M. J., Arbiser, J. L., Santini, E., & Klann, E. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.028 · Cited by 83
Brandt, C., Hillmann, P., Noack, A., Römermann, K., Öhler, L. A., Rageot, D., Beaufils, F., Melone, A., Sele, A., Wymann, M. P., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.002 · Cited by 84
“The allosteric mTORC1 inhibitors (“rapalogs”) rapamycin and everolimus have positive effects on behavior, reduce tumor formation, and suppress seizures in TSC mouse models (Meikle et al., 2008; Zeng et al., 2008; Ehninger et al., 2008).”
BackgroundDeletion of CTNNB1 in inhibitory circuitry contributes to autism-associated behavioral defects
Dong, F., Jiang, J. H., McSweeney, C., Zou, D., Liu, L., & Mao, Y. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw131 · Cited by 95
TORC1‐dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice
Abs, E., Goorden, S. M. I., Schreiber, J., Overwater, I. E., Hoogeveen‐Westerveld, M., Bruinsma, C. F., Aganović, E., Borgesius, N. Z., Nellist, M. D., & Elgersma, Y. (2013) · Annals of Neurology · doi:10.1002/ana.23943 · Cited by 94
“The changes in L-LTP are in line with the role of TORC1 signaling in the protein-synthesis phase of LTP.8,28 Passive membrane properties, such as RMP and RIN, were normal in the Tsc1f/2 mutant cells, suggesting that the hyperexcitability and reduced threshold for eliciting APs may result from changes in the expression…”
BackgroundMethodInfluentialLo‐Castro, A., & Curatolo, P. (2013) · Brain and Development · doi:10.1016/j.braindev.2013.04.013 · Cited by 97
Zeng, L., Bero, A. W., Zhang, B., Holtzman, D. M., & Wong, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.020 · Cited by 87
Electrocorticographic evidence of perituberal cortex epileptogenicity in tuberous sclerosis complex
Ma, T. S., Elliott, R. E., Ruppe, V., Devinsky, O., Kuzniecky, R., Weiner, H. L., & Carlson, C. (2012) · Journal of Neurosurgery Pediatrics · doi:10.3171/2012.8.peds1285 · Cited by 82
Autism spectrum disorders and epilepsy: Moving towards a comprehensive approach to treatment
Tuchman, R. F., Alessandri, M., & Cuccaro, M. L. (2010) · Brain and Development · doi:10.1016/j.braindev.2010.05.007 · Cited by 93
“[183] Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al.”
BackgroundAnderl, S., Freeland, M., Kwiatkowski, D. J., & Goto, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr393 · Cited by 81
Self-citationPerturbed proteostasis in autism spectrum disorders
Louros, S. R., & Osterweil, E. K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13723 · Cited by 99
Troca-Marín, J. A., Alves-Sampaio, A., & Montesinos, M. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0011-11.2011 · Cited by 85
“Interestingly, the mTOR pathway is hyperactivated in murine models of at least two other mental retardation diseases, tuberous sclerosis (Ehninger et al., 2008) and fragile X (Sharma et al., 2010), and it is emerging as a potential drug target to restore cognitive impair- syndrome.”
BackgroundHussain, S., Feldman, A. L., Das, C., Ziesmer, S. C., Ansell, S. M., & Galardy, P. J. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01389-12 · Cited by 82
Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis
Franz, D. N. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.93 · Cited by 78
Overview of Mouse Models of Autism Spectrum Disorders
Bey, A. L., & Jiang, Y. (2014) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0566s66 · Cited by 95
“The impaired memory phenotype is rescued by treatment with rapamycin (Ehninger et al., 2008; Sato et al., 2012).”
BackgroundEpilepsy and Tsc2 Haploinsufficiency Lead to Autistic-Like Social Deficit Behaviors in Rats
Waltereit, R., Japs, B., Schneider, M., de Vries, P. J., & Bartsch, D. (2011) · Behavior Genetics · doi:10.1007/s10519-010-9399-0 · Cited by 66
“behavior as well (Waltereit et al. 2006; Goorden et al. 2007; Ehninger et al. 2008 ).”
BackgroundConsolidation and translation regulation: Figure 1.
Gal-Ben-Ari, S., Kenney, J. W., Ounalla-Saad, H., Taha, E., David, O., Levitan, D., Gildish, I., Panja, D., Pai, B., Wibrand, K., et al. (2012) · Learning & Memory · doi:10.1101/lm.026849.112 · Cited by 79
“In studies with TSC2 heterozygous knockout mice, facilitated late CA1–LTP was observed alongside deficient contextual LTM, which was rescued by systemic rapamycin injection (Ehninger et al. 2008).”
BackgroundTherapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis
McDaniel, S. S., & Wong, M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.02.037 · Cited by 85
Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases
Krab, L. C., Goorden, S. M. I., & Elgersma, Y. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.07.005 · Cited by 89
Zhang, Z., Wang, X., Zhang, D., Liu, Y., & Lin, L. (2019) · Aging · doi:10.18632/aging.101759 · Cited by 79
“Inhibition of mTOR was shown to reverse learning deficits in Tsc2+/− mice [33], and memory deficits induced by delta-9-tetrahydro-cannabinol in normal mice [34].”
BackgroundNeurobiology of autism gene products: towards pathogenesis and drug targets
Kleijer, K. T. E., Schmeisser, M. J., Krueger, D. D., Boeckers, T. M., Scheiffele, P., Bourgeron, T., Brose, N., & Burbach, J. P. H. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3403-3 · Cited by 75
“A misbalance may occur when the loop is disturbed, for instance by a gene mutation that affects one component, like in TSC1/2 or FMRP, while the loop remains relatively in balance when both opposing components are lost simultaneously, like in a TSC1/2-FMRP double mutant (Auerbach et al. 2011).”
BackgroundInfluentialKang, E.-B., & Cho, J.-Y. (2015) · Journal of Exercise Nutrition & Biochemistry · doi:10.5717/jenb.2015.15090806 · Cited by 72
Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy
Aronica, E., Specchio, N., Luinenburg, M. J., & Curatolo, P. (2023) · Brain · doi:10.1093/brain/awad048 · Cited by 74
“Cognitive deficits in Tsc2 mutant mice could be rescued by rapamycin treatment.(43) Sato et al.”
BackgroundTsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility
Kosillo, P., Doig, N. M., Ahmed, K. M., Agopyan-Miu, A. H. C. W., Wong, C. D., Conyers, L., Threlfell, S., Magill, P. J., & Bateup, H. S. (2019) · Nature Communications · doi:10.1038/s41467-019-13396-8 · Cited by 77
Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
De Rubeis, S., & Bagni, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9087-2 · Cited by 73
“Genetic manipulation of some components of mTOR signal cascade, such as TSC2, results in synaptic plasticity defects and behavioral anomalies in mice (Ehninger et al. 2008a; Hoeffer et al. 2008).”
Lao, T., Glass, K., Qiu, W., Polverino, F., Gupta, K., Morrow, J. D., Mancini, J. D., Vuong, L., Perrella, M. A., Hersh, C. P., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0137-3 · Cited by 75
“It is not unprecedented to observe significant phenotypic changes in heterozygous mice with deficiency of genes that are crucial for morphogenesis, such as BECN1 [32], TSC2 [33],”
BackgroundCuratolo, P., & Maria, B. L. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52891-9.00038-5 · Cited by 89
Discovery of NV-5138, the first selective Brain mTORC1 activator
Sengupta, S., Giaime, E., Narayan, S., Hahm, S., Howell, J., O’Neill, D., Vlasuk, G. P., & Saiah, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40693-5 · Cited by 72
Lee, N. Y., Woodrum, C., Nobil, A. M., Rauktys, A., Messina, M. P., & Dabora, S. L. (2009) · BMC Pharmacology · doi:10.1186/1471-2210-9-8 · Cited by 76
“Furthermore, rapamycin and some of its analogs have successfully treated TSCrelated tumors, seizures, and cognitive defects in relevant rodent disease models [16-22].”
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
“Heterozygous TSC mouse models have subtle NDD phenotypes such as cognitive deficits and social impairments but do not show obvious TSC lesions or seizures (Ehninger et al. 2008; Goorden et al. 2007).”
BackgroundThe Gut-Immune-Brain Axis in Autism Spectrum Disorders; A Focus on Amino Acids
van Sadelhoff, J. H. J., Perez Pardo, P., Wu, J., Garssen, J., van Bergenhenegouwen, J., Hogenkamp, A., Hartog, A., & Kraneveld, A. D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00247 · Cited by 71
Neurodevelopmental Behavioral and Cognitive Disorders
Jeste, S. (2015) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000466661.89908.3c · Cited by 90
“For instance, based on the known mechanisms of TSC1 and TSC2 involving regulation of the mechanistic target of rapamycin (mTOR) pathway, mTOR inhibitors have been found to reverse cognitive and social impairments in mouse models of tuberous sclerosis complex after short courses of treatment.(68) These promising findin…”
BackgroundTranslational Control Mechanisms in Long-lasting Synaptic Plasticity and Memory
Gkogkas, C., Sonenberg, N., & Costa-Mattioli, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.154476 · Cited by 71
Characterizing autism spectrum disorders by key biochemical pathways
Subramanian, M., Timmerman, C. K., Schwartz, J. L., Pham, D. L., & Meffert, M. K. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00313 · Cited by 73
Hino, O., & Kobayashi, T. (2016) · Cancer Science · doi:10.1111/cas.13116 · Cited by 93
A paternal methyl donor-rich diet altered cognitive and neural functions in offspring mice
Ryan, D. P., Henzel, K. S., Pearson, B. L., Siwek, M. E., Papazoglou, A., Guo, L., Paesler, K., Yu, M., Müller, R., Xie, K., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.53 · Cited by 76
Self-citationControl of Synaptic Plasticity and Memory via Suppression of Poly(A)-Binding Protein
Khoutorsky, A., Yanagiya, A., Gkogkas, C. G., Fabian, M. R., Prager‐Khoutorsky, M., Cao, R., Gamache, K., Bouthiette, F., Parsyan, A. E., Sorge, R. E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.025 · Cited by 77
“Treatment with the mTOR inhibitor, rapamycin, reversed the learning and memory deficits, indicating that enhanced mTOR activity—and probably translation—are responsible for memory deficits (Ehninger et al., 2008).”
Bolton, P., Clifford, M., Tye, C., Maclean, C. J., Humphrey, A., le Maréchal, K., Higgins, N. J., Neville, B. G. R., Rijsdjik, F., The Tuberous Sclerosis 2000 Study Group, et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715000264 · Cited by 69
Mechanism-Based Treatment in Tuberous Sclerosis Complex
Jülich, K., & Sahin, M. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.12.002 · Cited by 71
The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
Feliciano, D. M. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00039 · Cited by 69
“These changes cause seizures by P16, learning deficits, and behavioral issues perhaps (Goorden et al., 2007; Ehninger et al., 2008; Auerbach et al., 2011; Lozovaya et al., 2014).”
BackgroundEhninger, D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.015 · Cited by 71
Self-citationReversibility of functional deficits in experimental models of Rett syndrome
Cobb, S., Guy, J., & Bird, A. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380498 · Cited by 67
Current Approaches and Future Directions for the Treatment of mTORopathies
Karalis, V., & Bateup, H. S. (2021) · Developmental Neuroscience · doi:10.1159/000515672 · Cited by 67
Retrograde Changes in Presynaptic Function Driven by Dendritic mTORC1
Henry, F. E., McCartney, A. J., Neely, R., Perez, A. S., Carruthers, C. J. L., Stuenkel, E. L., Inoki, K., & Sutton, M. A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2149-12.2012 · Cited by 71
“Animal studies have clearly implicated mTORC1 in hippocampal synaptic plasticity and in the formation of long-term hippocampal-dependent memories (Ehninger et al., 2008; Gkogkas et al., 2010; Hoeffer and Klann, 2010).”
BackgroundThe mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease
Talboom, J. S., Velazquez, R., & Oddo, S. (2015) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2015.8 · Cited by 67
Autism spectrum disorder: prospects for treatment using gene therapy
Benger, M., Kinali, M., & Mazarakis, N. D. (2018) · Molecular Autism · doi:10.1186/s13229-018-0222-8 · Cited by 80
Cassano, T., Magini, A., Giovagnoli, S., Polchi, A., Calcagnini, S., Pace, L., Lavecchia, M. A., Scuderi, C., Bronzuoli, M. R., Ruggeri, L., et al. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.011 · Cited by 66
Targeted treatment trials for tuberous sclerosis and autism: no longer a dream
Şahin, M. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.04.008 · Cited by 70
“Notably, a brief 5-day treatment with rapamycin in adult mice rescued not only the synaptic plasticity, but also learning and memory deficits in this animal model [35].”
Emerging Treatments in the Management of Tuberous Sclerosis Complex
Kohrman, M. H. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.02.015 · Cited by 66
Moavero, R., Benvenuto, A., Gialloreti, L. E., Siracusano, M., Kotulska, K., Weschke, B., Riney, K., Jansen, F. E., Feucht, M., Kršek, P., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060788 · Cited by 66
Self-citationUddin, M. S., Rahman, M. A., Kabir, M. T., Behl, T., Mathew, B., Perveen, A., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · IUBMB Life · doi:10.1002/iub.2324 · Cited by 69
Kirsten, T. B., Chaves-Kirsten, G. P., Bernardes, S., Scavone, C., Sarkis, J. E., Bernardi, M. M., & Felicio, L. F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134565 · Cited by 65
“For example, it has been postulated that constitutively increased mTOR signaling could be offset by rapamycin, an mTOR inhibitor [85].”
BackgroundEpilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments
Sampson, J. R., & Saxena, A. (2015) · Seminars in Neurology · doi:10.1055/s-0035-1552616 · Cited by 69
Kılınçaslan, A., Kök, B. E., Tektürk, P., Yalçınkaya, C., Özkara, Ç., & Yapıcı, Z. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0100 · Cited by 65
“Positive outcomes in the reversal of learning and social deficits have been observed in TSC mouse models with sirolimus (Ehninger et al. 2008; Sato et al. 2012; Tsai et al. 2012).”
Mouse Models of Autism: Testing Hypotheses About Molecular Mechanisms
Roullet, F., & Crawley, J. N. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_113 · Cited by 68
“…synaptic connections, dendritic spines, and electrophysiological measures of synaptic plasticity are being tested in mouse models of neurodevelopmental disorders (Beckel-Mitchener and Greenough 2004; Dolen et al. 2007; Lauterborn et al. 2007; Ehninger et al. 2008a; Sudhof 2008; Zhou et al. 2009).”
BackgroundMethodLin, T. V., Hsieh, L., Kimura, T., Malone, T. J., & Bordey, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605740113 · Cited by 67
Zeidán‐Chuliá, F., de Oliveira, B.-H., Salmina, A. B., Casanova, M. F., Gelain, D. P., Noda, M., Verkhratsky, A., & Moreira, J. C. F. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.227 · Cited by 67
“rescue synaptic plasticity and reverse the abnormal late phase of long-term potentiation.(20) These results encourage future clinical trials with TOR inhibitors as pharmacological treatment of ASD.”
ResultStafstrom, C. E., Staedtke, V., & Comi, A. M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00087 · Cited by 73
Rett Syndrome: From Bed to Bench
Weng, S.-M., Bailey, M. E. S., & Cobb, S. (2011) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2011.08.002 · Cited by 68
Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
Lam, C. G., Bouffet, É., Tabori, U. Y., Mabbott, D., Taylor, M. D., & Bartels, U. K. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22298 · Cited by 61
Kim, S.-H., Speirs, C. K., Solnica‐Krezel, L., & Ess, K. C. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.005587 · Cited by 61
“These animals were also shown to have deficits in hippocampus-dependent learning tasks, and these deficits were suppressed by rapamycin treatment (Ehninger et al., 2008).”
BackgroundCuratolo, P., Aronica, E., Jansen, A., Jansen, F. E., Kotulska, K., Lagae, L. G., Moavero, R., & Jóźwiak, S. (2015) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2015.12.005 · Cited by 63
Current Management of Tuberous Sclerosis Complex
Krueger, D. A., & Franz, D. N. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00004 · Cited by 67
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway
Chen, X., Wang, S., Zhou, Y., Han, Y., Li, S., Xu, Q., Xu, L., Zhu, Z., Deng, Y., Yu, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02531-y · Cited by 62
Self-citationHasskarl, J. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_23 · Cited by 67
mTOR in health and in sickness
Liko, D., & Hall, M. N. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1326-7 · Cited by 63
“that are reversible by rapamycin treatment [68, 67].”
Sirolimus Treatment in Sturge-Weber Syndrome
Sebold, A. J., Day, A. M., Ewen, J. B., Adamek, J. H., Byars, A. W., COHEN, B. A., Kossoff, E. H., Mizuno, T., Ryan, M., Sievers, J. W., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.10.013 · Cited by 62
Light phase testing of social behaviors: not a problem
Yang, M., Weber, M. D., & Crawley, J. N. (2008) · Frontiers in Neuroscience · doi:10.3389/neuro.01.029.2008 · Cited by 69
Ryther, R. C. C., & Wong, M. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0276-5 · Cited by 60
“Tsc2+/− mice [26] Adult (n/a) n/a n/a n/a n/a + n/a n/a”
Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets
Baranova, J., Dragunas, G., Botelho, M. C. S., Ayub, A. L. P., Bueno-Alves, R., Alencar, R. R., Papaiz, D. D., Sogayar, M. C., Ulrich, H., & Correa, R. G. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00882-7 · Cited by 69
Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis
Franz, D. N., & Weiss, B. D. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0269-4 · Cited by 58
Neurodegenerative pathways as targets for acquired epilepsy therapy development
Casillas-Espinosa, P. M., Ali, I. Y., & O'Brien, T. J. (2020) · Epilepsia Open · doi:10.1002/epi4.12386 · Cited by 65
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.